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Abstract
Background: Patients prescribed intravenous (IV) glycopeptides usually remain in hospital until
completion of this treatment. Some of these patients could be discharged earlier if a switch to an
oral antibiotic was made. This study was designed to identify the percentage of inpatients currently
prescribed IV glycopeptides who could be discharged earlier if a switch to an oral agent was used,
and to estimate the number of bed days that could be saved. We also aimed to identify the patient
group(s) most likely to benefit, and to estimate the number of days of IV therapy that could be
prevented in patients who remained in hospital.
Methods: Patients were included if they were prescribed an IV glycopeptide for 5 days or more.
Predetermined IV to oral antibiotic switch criteria and discharge criteria were applied. A multiple
logistic regression model was used to identify the characteristics of the patients most likely to be
suitable for earlier discharge.
Results: Of 211 patients, 62 (29%) could have had a reduced length of stay if they were treated
with a suitable oral antibiotic. This would have saved a total of 649 inpatient days (median 5 per
patient; range 1–54). A further 31 patients (15%) could have switched to oral therapy as an inpatient
thus avoiding IV line use. The patients most likely to be suitable for early discharge were those with
skin and soft tissue infection, under the cardiology, cardiothoracic surgery, orthopaedics, general
medical, plastic surgery and vascular specialities, with no high risk comorbidity and less than five
other regularly prescribed drugs.
Conclusion: The need for glycopeptide therapy has a significant impact on length of stay. Effective
targeting of oral antimicrobials could reduce the need for IV access, allow outpatient treatment and
thus reduce the length of stay in patients with infections caused by antibiotic resistant gram-positive
bacteria.
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Background
The incidence of infection with resistant gram-positive
organisms has increased dramatically over the past 10
years [1]. In the UK, this relates mainly to hospital-
acquired infections. However, there are also serious
worldwide concerns about community-acquired infec-
tions with resistant organisms [2,3]. Methicillin resistant
Staphylococcus aureus (MRSA) is the single most important
contributor to antimicrobial resistant nosocomial infec-
tions [4].
One consequence of the increase in antimicrobial resist-
ance among gram-positive bacteria is an increase in the
use of glycopeptides. These generally require intravenous
(IV) administration, resulting in an increase in the use of
IV lines. This in turn results in reduced mobility, and
increased risk of line-related infections. Presence of IV
lines is the most significant risk factor for hospital-
acquired bacteraemia and endocarditis [5,6]. Use of van-
comycin, the most widely used glycopeptide, is also asso-
ciated with nephrotoxicity [7,8] and requires
individualised dosing and monitoring of serum levels.
Except in rare examples of effective home IV programmes
[9], glycopeptide treatment inevitably means that the
individual must stay in hospital. There are well-recognised
adverse consequences of IV line use and hospitalisation,
particularly in older and more seriously ill patients [10].
In contrast, many infections caused by methicillin sensi-
tive S. aureus can be treated effectively with oral antibiot-
ics, or a few days of IV antibiotics followed by oral therapy
for the remainder of the course. Where a suitable oral
agent exists, IV to oral switch programmes have been
shown to be highly effective [11-13].
Until recently, there have been no effective single oral
agents for the treatment of many resistant gram-positive
infections, and there are no measures of the likely impact
on length of stay if a suitable agent was to become availa-
ble. However, linezolid, an antimicrobial with activity
against MRSA that can be given orally, was licensed in the
UK in 2001 and is at least as effective as glycopeptides
[14,15]. Unfortunately however, linezolid is significantly
more expensive than glycopeptides, and there are con-
cerns that widespread use may lead to the development of
resistance [16]. It may therefore be inappropriate to use
linezolid in all inpatients with resistant gram-positive
infections, so targeting those patients most likely to bene-
fit by being discharged earlier may be the most appropri-
ate approach.
The aims of this study were to explore the potential
impact of substituting an equally effective oral agent for IV
glycopeptides on IV line use and length of stay, and to
identify the patient groups most likely to benefit. Specific
objectives were:
• to identify the percentage of patients currently pre-
scribed IV glycopeptides who could be discharged earlier
if an oral agent was used;
￿ to estimate the number of inpatient days that could be
saved;
￿ to identify the groups of patients most likely to be suit-
able for earlier discharge if an oral agent was used;
￿ to identify the additional number of days of IV antibi-
otic treatment that could be prevented by using an oral
agent in hospitalised patients.
Methods
Setting
The study took place in a 1026 bed NHS teaching hospital
trust in west London, on two main hospital sites, and
across a broad range of general, regional and tertiary refer-
ral specialties. In accordance with the trust's antibiotic
guidelines, vancomycin was used as the first line glyco-
peptide. Guidelines suggested the most appropriate initial
dose based on age, weight and renal function; these also
advised that trough levels be taken before the third or
fourth dose and twice weekly thereafter. Teicoplanin was
approved only for the management of febrile neutropae-
nia or where vancomycin was contraindicated or not tol-
erated. Each ward was allocated a pharmacist who visited
the ward each weekday to check that all medication orders
were legal, clear and clinically appropriate for the patient.
The study was approved by the Hammersmith, Queen
Charlotte's and Acton Hospitals Research Ethics Commit-
tee.
Patient recruitment
Following development and piloting of the methods and
data collection processes, ward pharmacists in the two
hospital sites were asked to notify the study pharmacist
(ST) of all inpatients prescribed vancomycin or teico-
planin during a six-month period beginning February
2002. This was augmented by daily visits by the study
pharmacist to clinical areas with the highest use of glyco-
peptides, according to previous point-prevalence surveys
of anti-infective use in our trust [17].
The study pharmacist and either a microbiologist or Infec-
tious Diseases physician evaluated each patient after 48
hours of glycopeptide therapy. Patients were included in
the study if they fulfilled the following criteria:
1. Suspected or proven gram positive infection;
2. Expected to need glycopeptide treatment for at least 5
days as judged by the relevant medical or surgical team;BMC Infectious Diseases 2006, 6:94 http://www.biomedcentral.com/1471-2334/6/94
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3. Patient expected to survive with antibiotic therapy and
supportive care;
4. None of the following exclusion criteria:
4.1. Suspected or proven left-sided endocarditis, osteomy-
elitis or prosthetic infection where the prosthesis could
not be removed;
4.2. Per-protocol prescribing in haematology (where
teicoplanin was prescribed in response to failure of fever
resolution in neutropaenic patients without microbio-
logical or clinical evidence of gram positive infection);
4.3. Aged less than 16 years;
4.4. Pregnant or lactating female;
4.5. Patients with any other contraindication to linezolid.
Data collection
Patients meeting the inclusion criteria were assessed on
alternate days by the study pharmacist until the end of
glycopeptide treatment, discharge or death, whichever
was sooner, to find out if and when they met predeter-
mined criteria for either IV to oral switch, or discharge.
Patients who were enrolled but in whom it became appar-
ent that glycopeptide therapy was inappropriate, or who
required less than 5 days glycopeptide treatment for any
reason other than an unwanted reaction, were withdrawn
from the study.
The IV to oral switch criteria (tables 1 and 2) were adapted
from those already used in the trust [11] and elsewhere
[12,13]. The date on which each patient first fulfilled
these criteria was taken to be the date of theoretical IV to
oral switch.
Patients were graded as suitable for discharge on oral ther-
apy if, after fulfilling the IV-oral switch criteria, they then
fulfilled the discharge criteria (Table 3).
Data management and analysis
Data collection forms were used to capture the informa-
tion, which was anonymised and entered into a database
(Microsoft Access). A logistic regression analysis was used
to explore the characteristics of the patients most likely to
benefit from earlier discharge. Analysis was performed
using Genstat 5 (version 3.2; VSN International, Hemel
Hempstead, UK).
Results
A total of 211 patients fulfilled the study criteria, of whom
80 (38%) were female. Of these, 183 (87%) were pre-
scribed vancomycin as the sole glycopeptide, and 20 (9%)
teicoplanin alone. Eight patients (4%) received both
drugs sequentially during the data collection period. Of
these eight, six were changed from vancomycin to teico-
planin because of adverse effects, and two were started on
teicoplanin but then changed to vancomycin in accord-
ance with the trust's antibiotic policy. Adverse effects asso-
ciated with glycopeptide use were identified in 8 (4%)
patients. These were rash (4 patients), red man syndrome
(1), cellulitis secondary to IV line (1), extravasation (1)
and acute renal failure (1).
A total of 62 (29%) patients fulfilled the criteria for both
IV to oral switch and discharge on oral therapy during the
period they were prescribed an IV glycopeptide. For these
62 patients, 649 in-patient days could potentially have
been saved during the 6-month study period (median 5
per patient, range 1–54). In addition, a further 31 patients
(15%) fulfilled the IV to oral switch criteria but were not
suitable for discharge. For these patients, the length of
time they required IV therapy during their hospital stay
could have therefore been reduced and their IV lines taken
out earlier. An additional 247 days of IV therapy could
have been saved in these patients, representing a median
of 6 per patient (range 1–23).
The characteristics of the patients studied and their associ-
ations with suitability for early discharge or oral switch are
shown (Tables 4, 5, and 6). Nearly all the patients deemed
suitable for early discharge had infections of skin and soft
tissue. By confining attention to patients with infection in
this site (118 of the 211; 56%), it was found that five of
the eleven clinical specialities had no patients suitable for
early discharge; these were gastroenterology, haematol-
ogy/oncology, neurology, other surgical and respiratory.
For patients under the remaining specialities (100 of the
Table 1: IV to oral switch inclusion criteria used
1. Clinical status • Temperature less than 38°C for 24 hours
• White cell count normalising
• No unexplained tachycardia (Heart rate less than 100 beats 
per minute)
• Sensitivity received (if microbiology positive)
2. Oral absorption • Patient tolerates oral fluids
• No medical problems leading to reduced oral absorption (e. 
g. vomiting, diarrhoea, and gastrointestinal surgery)
• No surgical operation scheduled within next 36 hoursBMC Infectious Diseases 2006, 6:94 http://www.biomedcentral.com/1471-2334/6/94
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118 patients; 85%), multiple logistic regression models
for suitability for early discharge were tried against infect-
ing organism, number of comorbidities, presence of a
high risk comorbidity (atrial fibrillation, cancer, immobil-
ity, or insulin dependent diabetes mellitus), number of
other drugs (both as a quantitative variate and dichot-
omised as less than 5 or 5 or more), and speciality. A
model with all these terms had deviance 19.9 on 13
degrees of freedom. A model with only presence of a high
risk comorbidity, and five or more other drugs, had devi-
ance 15.4 on 2 degrees of freedom (p < 0.001). No other
terms were significant in the presence of these two.
The patients most likely to be suitable for early discharge
were therefore those with skin and soft tissue infection,
under the cardiology, cardiothoracic surgery, orthopaed-
ics, general medical, plastic surgery and vascular speciali-
ties, with no high risk comorbidity and who are
prescribed less than five other regular drugs. In this data
set, this identified 55 patients, 39 (71%) of whom were
deemed suitable for early discharge. The speciality with
the highest number of identified patients was orthopaed-
ics, with 20 patients of whom 15 (75%) were deemed suit-
able for early discharge.
Discussion
The availability of effective oral agents that can treat infec-
tions caused by resistant gram-positive organisms could
have a significant impact on the management of the
patients affected. The potential for hospital directed out-
patient oral therapy has three possible benefits. First, the
individual may be treated outside a hospital setting thus
releasing in-patient resources for reallocation. Second, in
the case of antibiotic resistant pathogens, the potential for
transmission within the health care setting is reduced.
Thirdly, the removal of IV lines reduces risk factors for
hospital-acquired bacteraemia, endocarditis and phlebi-
tis. While accurate financial accounting was not possible
as part of this study we have reported the number of bed
days saved as a marker of potential cost savings. The sav-
ings realised from a bed day saved needs to be balanced
against the cost of outpatient oral antibiotic treatment
and clinic follow up. However we still envisage substan-
tial savings with this approach.
One retrospective evaluation of the potential to switch to
linezolid has been carried out in Los Angeles, where 103
(58%) of 177 vancomycin courses could potentially have
been switched to oral linezolid [18]. In our study, which
was prospective, this figure was slightly less, at 45%. In
addition, 53% of the 103 Los Angeles patients were poten-
tially eligible for early discharge [18]. Again, this supports
our findings. What may differ is that because there are var-
iations in discharge and provision of effective home IV
services there is potentially more benefit to patients in the
UK and areas such as west London. In our study there was
a smaller overall proportion of patients (29% of the total)
compared with the Los Angeles group who could have
been discharged on oral treatment if such an agent had
been available. However, by targeting specific patient
groups, we found that 71% of these may be suitable for
earlier discharge.
It is interesting that in a number of cases there was a very
prolonged stay after patients fulfilled IV to oral switch cri-
teria. Possible contributors to a delay in discharge include
Table 3: Discharge on oral therapy criteria
1. Clinical status • Afebrile for at least 48 hours
• Tolerates normal diet
• IV access only required for glycopeptide therapy
• Physically independent/well enough for residential/nursing 
home care
2. Clinical team discharge policy • A YES answer to the question: "If this patient was on an 
equally effective oral antibiotic, could they be discharged 
today?"
Table 2: IV to oral switch exclusion criteria used
1. Continuing sepsis • Temperature less than 36°C or more than 38°C
• White cell count less than 4 × 109/L or more than 12 × 109/L
• Unexplained tachycardia (Heart rate greater than 100 beats 
per minute in last 12 hours)
2. Oral route compromised • Vomiting or severe diarrhoea
• Other ongoing or potential absorption problemBMC Infectious Diseases 2006, 6:94 http://www.biomedcentral.com/1471-2334/6/94
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occasional inappropriate antimicrobial use, subsequent
development of other hospital acquired infection or new
pathology, and logistic community or social issues.
Our study focused on identifying patients who met crite-
ria for IV to oral switch, and discharge, rather than those
who were actually discharged. Patients were not felt to be
eligible for IV to oral antibiotic switch if they did not meet
the predetermined IV to oral switch criteria (tables 1 and
2). In some settings a clinical decision may be made to
switch to oral therapy even in the presence of nasogastric
suction, ileus or bowel obstruction; in which case more
patients could potentially be switched. However for the
purposes of this study our criteria reflected current guide-
lines and practice in our hospital.
Pragmatically, a 24 hour observation period between IV-
oral switch and discharge is preferred by many clinicians.
This is the minimum time period implicit in the criteria
used in this study. In practice it is quite possible that dis-
charge would be earlier. However, we suggest that pro-
spective studies should now be carried out to find out if
our predictions are borne out in practice. Ideally this
would be a randomised controlled trial to compare out-
comes between inpatient and outpatient treatment.
Unfortunately it is likely that recruitment to this type of
study would present problems and patient choice may
dictate a significant preference for home treatment. Again,
this is an area that needs to be explored systematically. We
also suggest that a comparison is made with other options
such as an ambulatory IV service. While ambulatory IV
therapy retains the disadvantages of IV line use, it may be
a cost-effective approach in some settings [19].
Targeted IV to oral switch represents a significant oppor-
tunity to improve patient care and reduce the risks and
costs associated with hospitalisation. It clearly indicates
that different approaches to the management of clinical
infection need to be considered. The recent availability of
new antimicrobials makes implementation of this
approach possible and provides an opportunity to gather
an appropriate level of good evidence for the use of oral
agents in this setting.
Conclusion
The need for glycopeptide therapy for infections caused by
antibiotic resistant gram positive bacteria has a significant
impact on length of stay. Effective targeting of oral antimi-
crobials could reduce the need for IV access, allow outpa-
tient treatment and thus reduce length of stay. Evidence
from these data suggests that this could be effectively tar-
geted to particular groups of patients that can be identi-
fied at the start of treatment.
Table 5: Patients studied – site of infection
Infecting organism Total no. of patients in this 
category
Number of patients suitable 
for switch to oral therapy (% 
of patients with this infecting 
organism)
Number of patients suitable 
for switch to oral therapy and 
early discharge (% of patients 
with this infecting organism)
Coagulase negative staph 44 13 (30%) 9 (21%)
Enterococcus 17 5 (29%) 4 (24%)
MRSA 110 63 (57%) 38 (36%)
Other organisms 73  ( 4 3 % ) 3  ( 4 3 % )
Culture negative 33 9 (27%) 8 (24%)
Total = 211 93 62
Table 4: Patients studied – site of infection
Site of infection Total no. of patients in this 
category
Number of patients suitable 
for switch to oral therapy (% 
of patients with this site of 
infection)
Number of patients suitable 
for switch to oral therapy and 
early discharge (% of patients 
with this site of infection)
Blood 40 8 (20%) 3 (8%)
Sputum 40 2 (5%) 2 (5%)
Skin/Soft tissue 118 77 (65%) 54 (46%)
Other 13 6 (46%) 3 (23%)
Total 211 93 62BMC Infectious Diseases 2006, 6:94 http://www.biomedcentral.com/1471-2334/6/94
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